Daclatasvir dihydrochloride is a direct-acting antiviral agent belonging to the NS5A inhibitor class, used for the treatment of chronic hepatitis C virus (HCV) infections. To support pharmaceutical development… Read more
Daclatasvir dihydrochloride is a direct-acting antiviral agent belonging to the NS5A inhibitor class, used for the treatment of chronic hepatitis C virus (HCV) infections. To support pharmaceutical development and manufacturing, the analysis of this active pharmaceutical ingredient requires reliable reference standards to ensure accurate identification and rigorous quality control. This category includes a comprehensive range of highly characterized compounds, such as pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled versions of the parent drug. These reference materials are critical for laboratories conducting detailed impurity profiling, method validation, and stability testing to ensure full compliance with regulatory guidelines. By serving as precise analytical benchmarks, these compounds allow researchers to verify identity, confirm potency, and maintain consistent quality throughout the production lifecycle. Analytical professionals utilize these essential tools to mitigate risk and ensure the integrity of pharmaceutical formulations containing this potent antiviral medication.